Abstract
Background: Retinoblastoma is a sight and life-threatening embryonal tumor in children. Though chemotherapy is the main mode of therapy, evolving resistance remains a major obstacle in treatment success. The presence of cancer stem cells (CSC) is frequently reported to be responsible for chemoresistance in multiple tumors.
Objective: Our study aims to identify the molecular factors that facilitate the chemoresistance through cancer stem cells in retinoblastoma.
Methods: We developed etoposide and carboplatin resistant retinoblastoma (Y79) cell lines by stepwise drug increment treatment, validated with MTT and TUNEL assays. Colony forming and invasive ability were studied by soft-agar colony forming and transwell assays, respectively. Similar analysis in non-responsive retinoblastoma tumors were carried out by histopathology. Finally, expression of CSC/neuronal markers and ABC transporters were examined by quantitative PCR and protein expression of neuronal stem cell markers was confirmed by Western blot.
Results: Larger colony size of resistant cells in soft-agar assay provided evidence for increased selfrenewability. Histopathology in non-responsive tumors showed poorly differentiated cells predominantly. Besides, both resistant cell lines and non-responsive tumors showed increased invasion with higher expression of neuronal stem cell markers - SOX2, NANOG, OCT4 and ABC transporters - ABCB1 and ABCC3. Increased self-renewal ability and invasion along with overexpression of stemness markers in resistant cells and tumors provide evidence for stemness driving chemoresistance and invasion in retinoblastoma.
Conclusion: We have demonstrated Neuronal stem cell/CSC markers that facilitate the maintenance of cancer stem cells. Developing therapies targeting these factors will help in overcoming resistance and improving retinoblastoma treatment.
Keywords: Chemoresistance, ABC transporter, retinoblastoma, histopathology, cancer stem cell, neuronal stem cell markers.
Graphical Abstract
[http://dx.doi.org/10.1097/ICU.0000000000000002] [PMID: 24100372]
[http://dx.doi.org/10.1038/jhg.2015.62] [PMID: 26084579]
[http://dx.doi.org/10.4103/0971-5851.99731] [PMID: 22988349]
[http://dx.doi.org/10.1016/S0161-6420(91)32134-1] [PMID: 1682862]
[PMID: 9192801]
[http://dx.doi.org/10.7150/jca.19079] [PMID: 28819436]
[http://dx.doi.org/10.1038/ncb1589] [PMID: 17515932]
[http://dx.doi.org/10.1158/0008-5472.CAN-10-3340] [PMID: 21531766]
[http://dx.doi.org/10.1038/bjc.2014.528] [PMID: 25321191]
[http://dx.doi.org/10.1038/ng.127] [PMID: 18443585]
[PMID: 16179903]
[PMID: 17615543]
[PMID: 29181307]
[http://dx.doi.org/10.1007/s00418-014-1285-z] [PMID: 25326674]
[http://dx.doi.org/10.21769/BioProtoc.220]
[http://dx.doi.org/10.1111/j.1469-7580.2010.01269.x] [PMID: 20646110]]
[http://dx.doi.org/10.1038/nature13813] [PMID: 25252974]
[http://dx.doi.org/10.1186/s12885-017-3750-2] [PMID: 29162051]
[http://dx.doi.org/10.21873/anticanres.13858] [PMID: 31810908]
[http://dx.doi.org/10.1016/j.cell.2018.03.041]
[http://dx.doi.org/10.1038/cddiscovery.2016.105] [PMID: 28179999]
[http://dx.doi.org/10.18632/oncotarget.14230] [PMID: 28038467]
[http://dx.doi.org/10.1038/s41598-017-08971-2] [PMID: 28835684]
[http://dx.doi.org/10.1007/s11010-014-2260-7] [PMID: 25355160]
[http://dx.doi.org/10.1074/jbc.M800109200] [PMID: 18441325]
[http://dx.doi.org/10.18632/oncotarget.3325] [PMID: 25909162]
[http://dx.doi.org/10.1073/pnas.0804455105] [PMID: 18780787]
[http://dx.doi.org/10.1038/s41419-018-0919-9] [PMID: 30190481]
[http://dx.doi.org/10.3109/03009734.2012.659294] [PMID: 22376239]
[PMID: 27272814]
[http://dx.doi.org/10.1167/iovs.04-1290] [PMID: 16186322]
[http://dx.doi.org/10.1172/JCI41004] [PMID: 20051635]
[http://dx.doi.org/10.1371/journal.pone.0208194] [PMID: 30513115]
[http://dx.doi.org/10.21873/anticanres.12985] [PMID: 30396949]